Migrapen (Sumatriptan)

Sumatriptan, the active ingredient in Migrapen, is a Triptan (5‑HT1B/1D receptor agonist) presented as a subcutaneous injection for subcutaneous use. It is indicated for the acute treatment of migraine attacks in adult patients. The formulation is designed for rapid absorption, helping to relieve headache and associated migraine symptoms such as nausea, photophobia, and phonophobia.

GNH USA supplies Migrapen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality manufacturing standards and through reliable global distribution.

Sumatriptan acts on the serotonergic pathway to treat migraine and related headache disorders.

Migraine with aura: provides rapid relief of headache and associated neurological symptoms. Migraine without aura: reduces pain intensity and duration of attacks. Cluster headache: aborts acute cluster headache episodes when administered promptly.

Sumatriptan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or face - Nausea

Serious or Rare Side Effects: - Coronary artery spasm or myocardial ischemia - Serotonin syndrome when combined with other serotonergic agents - Anaphylactic reaction

When prescribing Migrapen, consider the following precautions.

Cardiovascular assessment: avoid use in patients with uncontrolled coronary artery disease or recent myocardial infarction. Medication review: assess concomitant use of other serotonergic drugs to reduce risk of serotonin syndrome. Pregnancy considerations: prescribe only if potential benefit justifies potential risk to the fetus. Age restrictions: safety and efficacy have not been established in children or adolescents. Drug interaction vigilance: monitor for interactions with ergot alkaloids and monoamine oxidase inhibitors. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Sumatriptan can interact with several medication classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans: additive vasoconstrictive effect may precipitate cardiovascular events. - Ergot alkaloids: combined vasoconstriction can lead to ischemia. - SSRIs, SNRIs, or other serotonergic agents: increased chance of serotonin syndrome. - Linezolid: potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance hypotensive effect. - CYP3A4 inhibitors (e.g., ketoconazole): may increase sumatriptan plasma levels.